Figure 1.

A, Study design: Patients in cohorts 1, 3, and 5 were treated with cabiralizumab and APX005M alone, as this doublet had not previously been administered to patients with cancer. Cohorts 2, 4, and 6 involved the addition of nivolumab to the other two drugs. Patients were enrolled concurrently in cohorts 2 and 3 and in cohorts 4 and 5. A standard 3+3 design was used. B–E, Example of tumor from a patient with melanoma treated on cohort 6 with increased CD4⁺ and CD8⁺ T-cell density in a right axillary lymph node at week 8 (C) compared with baseline (B). D shows baseline T-cell infiltration of tumor from a patient with RCC treated on cohort 1 in which there was a decrease in CD4⁺ and CD8⁺ T-cell density in a right flank mass at week 8 (E).